Glenmede Trust’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Glenmede Trust’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$147K	Hold	1,860	–	–	﹤0.01%	1351
2025 Q4	$153K	Buy	+1,860	New	+$144K	﹤0.01%	1311
2025 Q1	$118K	Hold	1,860	–	–	﹤0.01%	1266
2024 Q4	$124K	Hold	1,860	–	–	﹤0.01%	1289
2024 Q3	$130K	Hold	1,860	–	–	﹤0.01%	1272
2024 Q2	$121K	Hold	1,860	–	–	﹤0.01%	1239
2024 Q1	$120K	Hold	1,860	–	–	﹤0.01%	1226
2023 Q4	$122K	Sell	1,860 -1,579	-46%	-$91.8K	﹤0.01%	1189
2023 Q3	$196K	Hold	3,439	–	–	﹤0.01%	1098
2023 Q2	$216K	Hold	3,439	–	–	﹤0.01%	1079
2023 Q1	$216K	Sell	3,439 -1,860	-35%	-$120K	﹤0.01%	1084
2022 Q4	$336K	Hold	5,299	–	–	﹤0.01%	952
2022 Q3	$312K	Hold	5,299	–	–	﹤0.01%	939
2022 Q2	$305K	Hold	5,299	–	–	﹤0.01%	996
2022 Q1	$327K	Hold	5,299	–	–	﹤0.01%	1012
2021 Q4	$376K	Hold	5,299	–	–	﹤0.01%	996
2021 Q3	$396K	Hold	5,299	–	–	﹤0.01%	960
2021 Q2	$409K	Sell	5,299 -1,280	-19%	-$95.1K	﹤0.01%	939
2021 Q1	$485K	Hold	6,579	–	–	﹤0.01%	855
2020 Q4	$460K	Hold	6,579	–	–	﹤0.01%	860
2020 Q3	$372K	Hold	6,579	–	–	﹤0.01%	869
2020 Q2	$383K	Hold	6,579	–	–	﹤0.01%	832
2020 Q1	$367K	Hold	6,579	–	–	﹤0.01%	997
2019 Q4	$367K	Hold	6,579	–	–	﹤0.01%	997
2019 Q3	$310	Hold	6,579	–	–	﹤0.01%	1015
2019 Q2	$351	Hold	6,579	–	–	﹤0.01%	1000
2019 Q1	$362	Hold	6,579	–	–	﹤0.01%	979
2018 Q4	$309	Buy	+6,579	New	+$338K	﹤0.01%	975
2018 Q3	–	Sell	-1,579	Closed	-$86K	–	1719
2018 Q2	$86K	Hold	1,579	–	–	﹤0.01%	1297
2018 Q1	$74K	Hold	1,579	–	–	﹤0.01%	1486
2017 Q4	$74K	Hold	1,579	–	–	﹤0.01%	1486
2017 Q3	$78K	Hold	1,579	–	–	﹤0.01%	1488
2017 Q2	$66K	Hold	1,579	–	–	﹤0.01%	1501
2017 Q1	$66K	Hold	1,579	–	–	﹤0.01%	1501
2016 Q4	$61K	Hold	1,579	–	–	﹤0.01%	1549
2016 Q3	$66K	Hold	1,579	–	–	﹤0.01%	1517
2016 Q2	$58K	Hold	1,579	–	–	﹤0.01%	1525
2016 Q1	$60K	Hold	1,579	–	–	﹤0.01%	1465
2015 Q4	$79K	Hold	1,579	–	–	﹤0.01%	1426
2015 Q3	$72K	Hold	1,579	–	–	﹤0.01%	1474
2015 Q2	$92K	Hold	1,579	–	–	﹤0.01%	1438
2015 Q1	$87K	Sell	1,579 -1,800	-53%	-$97.3K	﹤0.01%	1505
2014 Q4	$169K	Sell	3,379 -290	-8%	-$14.2K	﹤0.01%	1369
2014 Q3	$168K	Buy	+3,669	New	+$165K	﹤0.01%	1239

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Glenmede Trust's PBE Position: Q1 2026 in Review

Glenmede Trust held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q1 2026 at 1,860 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #1351.

Glenmede Trust first reported a position in PBE in Q3 2014 and has held it in 44 quarters since. The position peaked at $485K in Q1 2021. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

Glenmede Trust held 1,860 shares of Invesco Biotechnology & Genome ETF worth $147K as of Q1 2026.
Glenmede Trust left its Invesco Biotechnology & Genome ETF share count unchanged in Q1 2026.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2026, its #1351 holding.
Glenmede Trust first reported a position in Invesco Biotechnology & Genome ETF in Q3 2014 and has held it in 44 quarters since.
Glenmede Trust's Invesco Biotechnology & Genome ETF position peaked at $485K in Q1 2021.
100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.